U.S. markets open in 4 hours 25 minutes
  • S&P Futures

    3,712.25
    +42.25 (+1.15%)
     
  • Dow Futures

    29,612.00
    +269.00 (+0.92%)
     
  • Nasdaq Futures

    11,466.00
    +149.75 (+1.32%)
     
  • Russell 2000 Futures

    1,686.30
    +23.80 (+1.43%)
     
  • Crude Oil

    78.01
    +1.30 (+1.69%)
     
  • Gold

    1,643.50
    +10.10 (+0.62%)
     
  • Silver

    18.64
    +0.16 (+0.87%)
     
  • EUR/USD

    0.9625
    +0.0013 (+0.13%)
     
  • 10-Yr Bond

    3.8780
    0.0000 (0.00%)
     
  • Vix

    31.02
    +1.10 (+3.68%)
     
  • GBP/USD

    1.0807
    +0.0124 (+1.16%)
     
  • USD/JPY

    144.3600
    -0.3200 (-0.22%)
     
  • BTC-USD

    20,153.37
    +889.64 (+4.62%)
     
  • CMC Crypto 200

    460.15
    +27.05 (+6.24%)
     
  • FTSE 100

    7,023.91
    +2.96 (+0.04%)
     
  • Nikkei 225

    26,571.87
    +140.32 (+0.53%)
     

Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences

·2 min read

BOSTON, March 02, 2022--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that management will be presenting at the following investor conferences:

  • Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022 at 10:30 a.m. ET

  • Barclays Global Healthcare Conference on Tuesday, March 15, 2022 at 3:20 p.m. ET

A live webcast of Ironwood’s presentations will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. To access the webcasts, please log on to the Ironwood website approximately 15 minutes prior to the start times to ensure adequate time for any software downloads that may be required. A replay of the webcasts will be available on Ironwood’s website for 14 days following the conferences.

About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (Nasdaq: IRWD) is a leading gastrointestinal (GI) healthcare company on a mission to advance the treatment of GI diseases and redefine the standard of care for GI patients. We are pioneers in the development of LINZESS® (linaclotide), the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Under the guidance of our seasoned industry leaders, we continue to build upon our history of GI innovation and challenge what has been done before to shape what the future holds. We keep patients at the heart of our R&D and commercialization efforts to reduce the burden of GI diseases and address significant unmet needs.

Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts.

We routinely post information that may be important to investors on our website at www.ironwoodpharma.com. In addition, follow us on Twitter and on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220302005153/en/

Contacts

Investors:
Matt Roache, 617-621-8395
Director, Investor Relations
mroache@ironwoodpharma.com